Applied Health Economics and Health Policy

Title Publication Date Language Citations
Financial Impact of Alternative Pricing Benchmarks for Physician-Dispensed Drugs in the California Workers’ Compensation System2018/11/28English
Comment on: “Economic Implications of Pathogen Reduced and Bacterially Tested Platelet Components: A US Hospital Budget Impact Model”2019/01/25English
Authors’ Reply to Mintz: “Economic Implications of Pathogen Reduced and Bacterially Tested Platelet Components: A US Hospital Budget Impact Model”2019/01/25English
Acknowledgement to Referees2019/10/29English
Using the Economics of Certification to Improve the Safety and Quality of Male Circumcision in Developing Countries2012/03/01English
What Explains Willingness to Pay for Smoking-Cessation Treatments – Addiction Level, Quit-Rate Effectiveness or the Opening Bid?2012/11/01English
Clopidogrel versus Aspirin in Patients with Atherothrombosis2012/09/01English
Alcohol Reform in Viet Nam2012/09/01English
Erratum2011/09/01English
Acknowledgement2011/11/01English
Gary Buurman, 1944–20102010/05/01English
Organization and Estimated Patient-Borne Costs of Oral Anticoagulation Therapy in Italy2010/03/01English
The Case of Penny Wise but Access and Quality of Care Foolish2015/03/12English
Evolving Evidence-Based Value Assessment of One-Time Therapies: Tisagenlecleucel as a Case Study2024/04/29English
Comment on: “Cost Effectiveness of Tiotropium in Patients with Asthma Poorly Controlled on Inhaled Glucocorticosteroids and Long-Acting β-Agonists”2015/12/30English
What Explains Willingness to Pay for Smoking-Cessation Treatments —Addiction Level, Quit-Rate Effectiveness or the Opening Bid?2012/11/01English
Do Higher-Priced Generic Medicines Enjoy a Competitive Advantage Under Reference Pricing?2012/11/01English
Insensitivity to Scope in Contingent Valuation Studies2012/11/01English
Acknowledgement2012/11/01English
Economic Implications of Rasburicase Treatment in Adult Patients with Tumour Lysis Syndrome2012/11/01English
Cost Effectiveness of Guanfacine Extended-Release versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder2012/11/01English
Inclusion of Compliance and Persistence in Economic Models2012/11/01English
Healthcare Costs Associated with Change in Body Mass Index in Patients with Type 2 Diabetes Mellitus in Spain2012/11/01English
Cost Effectiveness of Guanfacine Extended-Release versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder2012/11/01English
Acknowledgement to Referees2016/11/09English
Authors’ Reply to Gandjour: “The Role of Chronic Disease, Obesity, and Improved Treatment and Detection in Accounting for the Rise in Healthcare Spending Between 1987 and 2011”2016/02/25English
Authors’ Reply to Liedgens and Henske: “Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective”2013/08/02English
Erratum to: Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland2013/10/30English
How Did the Affordable Care Act Affect Risky Health Behaviors?2021/12/08English
Using a Formal Strategy of Priority Setting to Mitigate Austerity Effects Through Gains in Value: The Role of Program Budgeting and Marginal Analysis (PBMA) in the Brazilian Public Healthcare System2020/05/29English